Pancreatic Cancer

Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

Incyte Study ID:
INCB 18424-362
CT.gov ID:
NCT02117479
Eudra ID:
N/A
Sponsor:
Incyte Corporation
Collaborator:
N/A
Study Contact Information:
844-23JANUS
Other
Subscribe to UpdatesContact Us

Clinical Study Purpose

Determining the efficacy, based upon overall survival, of ruxolitinib added to capecitabine for the treatment of advanced or metastatic pancreatic cancer.

Clinical Study Summary

MEDICAL CONDITION(S)
  • Pancreatic Cancer
    • PRODUCT
  • Drug: Ruxolitinib
  • Drug: Placebo
  • Drug: Capecitabine
    • COLLABORATORS
    N/A
    DATE
    Mar 2014 - Feb 2016
    TYPE
    Interventional
    PHASE
    Phase 3
    SEX
    Female & Male
    AGE
    18+ years
    ACCEPTS HEALTHY VOLUNTEERS
    No

    Clinical Study Locations

    Name
    Contact Us
    Name
    Avondale, AZ, US
    Name
    Chandler, AZ, US
    Name
    Gilbert, AZ, US
    Name
    Glendale, AZ, US
    Name
    Hot Springs, AR, US
    Name
    Jonesboro, AR, US

    Key Inclusion and Exclusion Criteria

    Inclusion Criteria

    • Histologically or cytologically confirmed adenocarcinoma of the pancreas.
    • Advanced adenocarcinoma of the pancreas that is inoperable or metastatic.

    Exclusion Criteria

    • Received more than 1 prior regimen for advanced or metastatic disease.
    • Ongoing radiation therapy, radiation therapy administered within 30 days of enrollment.

    Protocol Summary

    Incyte Study ID:
    INCB 18424-362
    Primary Purpose:
    Treatment
    Allocation:
    Randomized
    Study Design:
    Parallel Assignment
    Masking:
    Double (Participant, Investigator)
    Interventions:
    Drug
    Enrollment:
    321
    Primary Outcome
    Open
    Secondary Outcome
    Open